newsfilter
← Latest News
GlobeNewswire·

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash Xilio may elect to cancel unexercised Series B or Series C warrants